Fig. 1: TINCR targeted miR-211-3p, and silencing miR-211-3p inhibited TAC-induced cardiac hypertrophy in vivo.
From: LncRNA TINCR improves cardiac hypertrophy by regulating the miR-211-3p-VEGFB-SDF-1α-CXCR4 pathway
A The predicted binding site for miR-211-3p and luciferase activity of TINCR wild-type or mutated reporters (n = 3). B The interaction between miR-211-3p and TINCR. C The relative expression of TINCR and miR-211-3p in rats treated with TAC or sham (n = 3). D The relative expression of miR-211-3p in rats with the indicated treatment (n = 3). E Heart weight to tibial length and cross-sectional areas of cardiomyocytes (n = 3). F Heart photo and H&E staining of heart sections. G The relative mRNA expression of ANP, BNP, β-MHC, and Col1 in rats (n = 3). H Western blot analysis of ANP and β-MHC in rats with the indicated treatment (n = 3). GAPDH was used as a loading and normalization control. I IHC staining of ANP and β-MHC. Data were from at least three independent assays. *P < 0.05, **P < 0.01, and ***P < 0.001.
